Neuropsychopharmacological profile in rodents of SR 57746A, a new, potent 5-HT1A receptor agonist.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Fundamental & Clinical Pharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry, Psychology

• Identifiers
  PMID 7904976
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antidepressant-like activity of 5-HT1A agonists measured with the forced swim test

  2005cited by this paper
• The staircase test: Some evidence of nonspecificity for anxiolytics

  2004cited by this paper
• The staircase test in mice: A simple and efficient procedure for primary screening of anxiolytic agents

  2004cited by this paper
• Disinhibitory effects of buspirone and low doses of sulpiride and haloperidol in two experimental anxiety models in rats: Possible role of dopamine

  2004cited by this paper
• Antidepressant-like action of 8-OH-DPAT, a 5-HT1A agonist, in the learned helplessness paradigm: evidence for a postsynaptic mechanism.

  1990cited by this paper
• Effects of anxiolytic and anxiogenic drugs on exploratory activity in a simple model of anxiety in mice.

  1989cited by this paper
• Exploration of mice in a black and white test box: validation as a model of anxiety.

  1989cited by this paper
• Effects of ipsapirone and BAY R 1531 on learned helplessness.

  1989cited by this paper
• Reversal of neuroleptic‐induced catalepsy by novel aryl‐piperazine anxiolytic drugs

  1988cited by this paper
• Different effects of intracerebral and systemic administration of buspirone in the forced swimming test: involvement of a metabolite.

  1988cited by this paper
• Blockade of alpha 2-adrenoceptors by 1-(2-pyrimidinyl)-piperazine (PmP) in vivo and its relation to the activity of buspirone.

  1988cited by this paper
• Actions of Buspirone in a Putative Model of Anxiety in the Mouse

  1988cited by this paper
• Reversal of helpless behavior in rats by putative 5-HT1A agonists.

  1988cited by this paper
• Alpha 2-adrenoceptor antagonist activity may account for the effects of buspirone in an anticonflict test in the rat.

  1988cited by this paper
• Potential antidepressant properties of 8-hydroxy-2-(di-n-propylamino)tetralin, a selective serotonin1A receptor agonist.

  1987cited by this paper
• Behavioral effects of several new anxiolytics and putative anxiolytics.

  1987cited by this paper
• Discriminative stimulus properties of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OHDPAT): implications for understanding the actions of novel anxiolytics.

  1987cited by this paper
• The role of putative 5-HT1A and 5-HT1B receptors in the control of feeding in rats.

  1987cited by this paper
• Pharmacological evidence for the involvement of 1-(2-pyridinyl)-piperazine (1-PmP) in the interaction of buspirone or gepirone with noradrenergic systems.

  1987cited by this paper
• Buspirone effects in an animal conflict procedure: comparison with diazepam and phenobarbital.

  1987cited by this paper
• (-)-Propranolol blocks the inhibition of serotonergic dorsal raphe cell firing by 5-HT1A selective agonists.

  1986cited by this paper
• Differential effects of 5-hydroxytryptamine1a selective drugs on the 5-HT behavioral syndrome.

  1986cited by this paper
• 1-(2-Pyrimidinyl)-piperazine as active metabolite of buspirone in man and rat.

  1986cited by this paper
• Shuttle-box deficits induced by inescapable shocks in rats: reversal by the beta-adrenoreceptor stimulants clenbuterol and salbutamol.

  1986cited by this paper
• Selective interaction of novel anxiolytics with 5-hydroxytryptamine1A receptors.

  1985cited by this paper
• The pharmacology of the hypothermic response in mice to 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). A model of presynaptic 5-HT1 function.

  1985cited by this paper
• Behavioral effects of nonbenzodiazepine anxiolytic drugs: a comparison of CGS 9896 and zopiclone with chlordiazepoxide.

  1985cited by this paper
• The involvement of subtypes of the 5-HT1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di-n-propylamino)tetralin in the rat.

  1984cited by this paper
• Buspirone: action on serotonin receptors in calf hippocampus.

  1983cited by this paper
• Neuropharmacological profile of MD 790501, a new benzamide derivative.

  1983cited by this paper
• EFFECTS OF DRUGS ON BEHAVIOUR OF AGGRESSIVE MICE

  1979cited by this paper
• The comparative efficacy of buspirone and diazepam in the treatment of anxiety.

  1979cited by this paper
• Climbing behaviour induced by apomorphine in mice: a potential model for the detection of neuroleptic activity.

  1978cited by this paper
• Depression: a new animal model sensitive to antidepressant treatments

  1977cited by this paper
• Behavioral despair in mice: a primary screening test for antidepressants.

  1977cited by this paper
• [Dissociation of two components of rat behaviour by psychotropic drugs. Utilization for studying anxiolytic drugs].

  1973cited by this paper
• Effects of centrally active drugs on four models of experimentally-induced aggregession in rodents.

  1969cited by this paper
• [Action of caffeine on the spontaneous motility of the mouse].

  1965cited by this paper
• Apomorphine-antagonism in rats.

  1960cited by this paper
• A Method for Evaluating both Non-Narcotic and Narcotic Analgesics

  1957cited by this paper
• A note on a simple apparatus for detecting neurological deficit in rats and mice.

  1957cited by this paper
• Comparative assays of antiepileptic drugs in mice and rats.

  1952cited by this paper

• Studies on neurobehavioural properties of Caralluma dalzielii N.E Br. aqueous aerial parts extract in mice.

  2024cites this paper
• Anxiolytic-Like Effect of Methanol Leaf Extract of Laggera aurita Linn. F. (Asteraceae) in Mice

  2018cites this paper
• Potential functional and pathological side effects related to off-target pharmacological activity.

  2017cites this paper
• Tests for Anxiolytic Activity

  2015cites this paper
• Targeting neuroprotection as an alternative approach to preventing and treating neuropathic pain

  2009cites this paper
• SR 57746A/xaliproden, a non-peptide neurotrophic compound: prospects and constraints for the treatment of nervous system diseases

  2009cites this paper
• THEMED ISSUE: GPCR RESEARCH PAPER 5-HT1A receptors are involved in the effects of xaliproden on G-protein activation, neurotransmitter release and nociception

  2009influential citation
• Pharmacokinetics of 6‐hydroxybuspirone and its enantiomers administered individually or following buspirone administration in humans

  2007cites this paper
• Reduced density of functional 5‐HT1A receptors in the brain, medulla and spinal cord of monoamine oxidase‐A knockout mouse neonates

  2006cites this paper
• Mapk Activation Via 5-Hydroxytryptamine 1A Receptor is Involved in the Neuroprotective Effects of Xaliproden

  2005cites this paper
• In vivo comparison of two 5-HT1A receptors agonists alnespirone (S-20499) and buspirone on locus coeruleus neuronal activity.

  2003cites this paper
• 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related

  2002cites this paper
• Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders

  2002cites this paper
• Effects of nitric oxide synthase inhibitors 7-NI, L-NAME, and L-NOARG in staircase test.

  2002cites this paper
• Animal Models of Integrated Serotoninergic Functions: Their Predictive Value for the Clinical Applicability of Drugs Interfering with Serotoninergic Transmission

  2000cites this paper
• Receptor binding profile and anxiolytic‐type activity of deramciclane (EGIS‐3886) in animal models

  1997cites this paper
• Comparative behavioural profiles of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine (1-PP) in the murine elevated plus-maze.

  1997cites this paper
• Psychotropic and neurotropic activity

  1997cites this paper
• SR 57746A: An Orally Active Non‐Peptide Compound with Neurotrophic and Neuroprotective Effects

  1997cites this paper
• Mechanisms of action of atypical antipsychotic drugs: a critical analysis

  1996cites this paper
• Evidence for Nerve Growth Factor‐Potentiating Activities of the Nonpeptidic Compound SR 57746A in PC12 Cells

  1995cites this paper
• Serotonergic mechanisms involved in the exploratory behaviour of mice in a fully automated two-compartment black and white text box.

  1995cites this paper
• Facilitating effects of SR 57746A on short‐term memory in an operant delayed alternation task in aged rats

  1995cites this paper
• Selective in vivo labelling of brain 5-HT1A receptors by [3H]WAY 100635 in the mouse.

  1994cites this paper
• Biochemical and electrophysiological properties of SR 57746A, a new, potent 5‐HT1A receptor agonist

  1993cites this paper